| Title: | Improved Time in Range and Postprandial Hyperglycemia with Canagliflozin in Combination with Teneligliptin : Secondary Analyses of the CALMER study |
| Authors: | Cho, Kyu Yong Browse this author |
| Nomoto, Hiroshi Browse this author →KAKEN DB |
| Nakamura, Akinobu Browse this author →KAKEN DB |
| Kawata, Shinichiro Browse this author |
| Sugawara, Hajime Browse this author |
| Takeuchi, Jun Browse this author |
| Nagai, So Browse this author →KAKEN DB |
| Omori, Kazuno Browse this author |
| Tsuchida, Kazuhisa Browse this author |
| Miya, Aika Browse this author |
| Shigesawa, Ikumi Browse this author |
| Tsuchida, Kenichi Browse this author |
| Yanagiya, Shingo Browse this author |
| Kameda, Hiraku Browse this author →KAKEN DB |
| Yokoyama, Hiroki Browse this author |
| Taneda, Shinji Browse this author |
| Kurihara, Yoshio Browse this author |
| Aoki, Shin Browse this author |
| Nishimoto, Naoki Browse this author →KAKEN DB |
| Atsumi, Tatsuya Browse this author →KAKEN DB |
| Miyoshi, Hideaki Browse this author →KAKEN DB |
| Keywords: | SGLT2 inhibitor |
| DPP-4 inhibitor |
| Post-Prandial Blood Glucose |
| Time in Range |
| Issue Date: | 10-Aug-2021 |
| Publisher: | John Wiley & Sons |
| Journal Title: | Journal of Diabetes Investigation |
| Volume: | 12 |
| Issue: | 8 |
| Start Page: | 1417 |
| End Page: | 1424 |
| Publisher DOI: | 10.1111/jdi.13498 |
| Abstract: | Aims/Introduction We recently reported the beneficial effect of the combination of SGLT2 inhibitor and DPP‐4 inhibitor on daily glycemic variability in patients with type 2 diabetes mellitus (T2DM). Additional favorable effects of combination therapy were explored in this secondary analysis. Materials and Methods The CALMER study was a multicenter, open‐label, prospective, randomized, parallel‐group comparison trial for T2DM involving continuous glucose monitoring (CGM) under meal tolerance tests (MTTs). Patients were randomly assigned to switch from teneligliptin to canagliflozin (SWITCH group) or to add canagliflozin to teneligliptin (COMB group). The CGM metrics, including time in target range (TIR), were investigated. Results All 99 participants (mean age: 62.3 years; mean HbA1c: 7.4%) completed the trial. TIR was increased in the COMB group (71.2% to 82.7%, p<0.001). The extent of the reduction in time above target range (TAR) was significantly larger in the COMB group compared with the SWITCH group (?14.8% vs. ?7.5%, p<0.01). Area under the curve values for glucose at 120 min after all MTTs were significantly decreased in the COMB group compared with the SWITCH group (p<0.05). Conclusions SGLT2 inhibitor combined with DPP‐4 inhibitor improved the quality of glycemic variability and reduced postprandial hyperglycemia compared with each monotherapy. |
| Rights: | http://creativecommons.org/licenses/by/4.0/ |
| Type: | article |
| URI: | http://hdl.handle.net/2115/82878 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
